NCT01636479View on ClinicalTrials.gov

Phase 1 Safety Testing of SAR405838

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 13, 2012

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions
Neoplasm Malignant
Interventions
DRUG

SAR405838

Pharmaceutical form: Capsule Route of administration: Oral

Trial Locations (7)

10021

Investigational Site Number 840002, New York

94805

Investigational Site Number 250001, Villejuif

02114

Investigational Site Number 840101, Boston

02115

Investigational Site Number 840001, Boston

1066 CX

Investigational Site Number 528001, Amsterdam

3075 EA

Investigational Site Number 528003, Rotterdam

3584 CX

Investigational Site Number 528002, Utrecht

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01636479 - Phase 1 Safety Testing of SAR405838 | Biotech Hunter | Biotech Hunter